Adults with COPD who used inhaled corticosteroids for more than 24 months faced higher risks for diabetes, osteoporosis, ...
For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...
Our latest study, published in The Lancet Respiratory Medicine, has revealed ... have experienced eosinophilic asthma or COPD ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
COPD is also associated with a significant health and economic burden due to recurrent acute exacerbations that require systemic corticosteroid medicine and/or antibiotics. Smoking and exposure to ...
Available treatments for COPD are mainly palliative ... IMD-1041 (Institute of Medicine and Molecular Design) is in Phase I trials. There are also several drugs in development that target the ...
COPD is also associated with a significant health and economic burden due to recurrent acute exacerbations that require systemic corticosteroid medicine and/or antibiotics. Smoking and exposure to ...
This may open up for new treatment strategies that target IL-26 to reduce inflammation and improve the quality of life for patients with COPD," says Anders Lindén, professor at the Institute of ...
10d
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
Results from BOREAS and the replicate NOTUS Phase 3 trial were published in The New England Journal of Medicine. In addition to COPD, Dupixent is approved in Japan in certain patients with atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results